| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Consolidation therapies revisited: weekly paclitaxel
|
Pecorelli, S.
|
|
|
13 |
S2 |
p. 208-211
|
artikel
|
| 2 |
Consolidation therapy revisited: intravenous chemotherapy
|
Markman, M.
|
|
|
13 |
S2 |
p. 204-207
|
artikel
|
| 3 |
Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy
|
Sorbe, B.
|
|
|
13 |
S2 |
p. 192-195
|
artikel
|
| 4 |
Cost-effectiveness studies in ovarian cancer
|
Szucs, T.D.
|
|
|
13 |
S2 |
p. 212-219
|
artikel
|
| 5 |
First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
|
Kristensen, G.B.
|
|
|
13 |
S2 |
p. 172-177
|
artikel
|
| 6 |
Improving first-line therapy of advanced ovarian cancer – the AGO Ovarian Cancer Study Group perspective
|
Du Bois, A.
|
|
|
13 |
S2 |
p. 169-171
|
artikel
|
| 7 |
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy
|
Piccart, M.J.
|
|
|
13 |
S2 |
p. 196-203
|
artikel
|
| 8 |
Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment?
|
González-Martín, A.
|
|
|
13 |
S2 |
p. 185-191
|
artikel
|
| 9 |
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
|
Piccart, M.J.
|
|
|
13 |
S2 |
p. 144-148
|
artikel
|
| 10 |
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5
|
Bookman, M.A.
|
|
|
13 |
S2 |
p. 149-155
|
artikel
|
| 11 |
Ovarian cancer treatment: what is new
|
Poveda, A.
|
|
|
13 |
S2 |
p. 241-250
|
artikel
|
| 12 |
Proteomic analysis for early detection of ovarian cancer: A realistic approach?
|
Stevens, E.V.
|
|
|
13 |
S2 |
p. 133-139
|
artikel
|
| 13 |
Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132
|
Muggia, F.M.
|
|
|
13 |
S2 |
p. 156-162
|
artikel
|
| 14 |
Systemic treatment policies in ovarian cancer: the next 10 years
|
Biagi, J.J.
|
|
|
13 |
S2 |
p. 231-240
|
artikel
|
| 15 |
The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
|
Baekelandt, M.
|
|
|
13 |
S2 |
p. 163-168
|
artikel
|
| 16 |
The role of anthracyclines in second-line therapy of ovarian cancer
|
Vermorken, J.B.
|
|
|
13 |
S2 |
p. 178-184
|
artikel
|
| 17 |
Translational research in ovarian cancer: a must
|
Hamilton, T.C.
|
|
|
13 |
S2 |
p. 220-230
|
artikel
|
| 18 |
What have we learned from ICON1 and ACTION?
|
Colombo, N.
|
|
|
13 |
S2 |
p. 140-143
|
artikel
|
Tijdschrift beschrijving